GlobeNewsWire
02 Jun 2026, 20:49 UTC · 1h ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
GlobeNewsWire
02 Jun 2026, 20:49 UTC · 1h ago
Story key points
4 claims · impact-rated
TriSalus Life Sciences (TLSI) cut its full-year revenue guidance to $54 million–$57 million, a $5.5 million reduction from previous targets. — Downward revisions to revenue guidance directly signal weakening fundamentals and lower future earnings expectations.
-0.60FDA clearance for TriNav Advance is delayed by approximately five months past the 30-day MDUFA review goal. — Delays in regulatory approvals for key products halt growth catalysts and push back potential revenue streams.
-0.50Pomerantz LLP is investigating TriSalus Life Sciences for potential securities fraud or unlawful business practices. — Legal investigations and potential class-action lawsuits create significant litigation risk and uncertainty for shareholders.
-0.40Continue reading
6 related stories
Search tags
TriSalus reported Q1 2026 revenue of $8.90 million, representing a 2.92% year-over-year decline. — A slight decline in quarterly revenue confirms a trend of slowing growth but is less impactful than the full-year guidance cut.
-0.20Ticker attribution
Model heads
The company is facing a securities fraud investigation, revenue declines, lowered guidance, and a significant stock price drop.
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
GlobeNewsWire
44m ago
